^
Association details:
| Biomarker: | TOP2A amplification |
|---|---|
| Cancer: | Breast Cancer |
| Regimen: | (5-fluorouracil + cyclophosphamide + epirubicin) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy
Published date:
04/28/2009
Excerpt:
In patients whose tumors showed TOP2A alterations (either amplifications or deletions), treatment with CEF was statistically significantly superior to treatment with CMF in terms of RFS (adjusted hazard ratio [HR] = 0.35, 95% confidence interval [CI] = 0.17 to 0.73, P = .005) and OS (adjusted HR = 0.33, 95% CI = 0.15 to 0.75, P = .008)....TOP2A gene alterations (amplifications or deletions) are associated with an increase in responsiveness to anthracycline-containing chemotherapy regimens.
DOI:
10.1093/jnci/djp067
